Summary of key clinical data from 2 large (>100 patients) multicenter, noncomparative studies (Korea and China) in Asian patients receiving lenalidomide/dexamethasone for relapsed or refractory multiple myeloma [<a href="#B17">17</a>, <a href="#B18">18</a>].

Download original image

Table 2Summary of key clinical data from 2 large (>100 patients) multicenter, noncomparative studies (Korea and China) in Asian patients receiving lenalidomide/dexamethasone for relapsed or refractory multiple myeloma [<a href="#B17">17</a>, <a href="#B18">18</a>].

^a)Primary efficacy population (safety population: N=199).

Abbreviations: BOR, bortezomib; CI, confidence interval; NR, not reported; OS, overall survival; PFS, progression-free survival; PR, partial response; THD, thalidomide; TTP, time to progression.

Blood Res 2015;50:7~18 https://doi.org/10.5045/br.2015.50.1.7